MedinCell announces the successful pricing of its Global Offering and raises €25 million
May 12, 2023
Previous PostPhase 1 data of mdc-TJK investigational long-acting injectable of olanzapine for schizophrenia patients, exhibited favorable characteristics of an extended-release profile
Next PostMedinCell launches a Global Offering for approximately 25 million euros
